Resources

READ

READ

READ

Could PBMs and Diagnostic Labs Find Synergies in the Healthcare Market?

Mission Possible:

Economics for Diagnostics            

Mission Possible

DX Companies Need to Control Their Own Market         

Mission Possible: 

Show less  —

CEO Hannah Mamuszka chaired sessions on Precision Medicine. For more on the event please visit PMLS 

virtual event: September 24-25, 2020

PRecision Diagnostics

Precision Medicine Leaders Summit

EVENTS

Hannah Mamuszka co-presented Tuesday August 26th at 2:50pm. The topic: Partnering to Rethink Real-World Data Development: Why Payers and Diagnostics Companies Should Come Together Early in Commercial Planning. Full event details HERE

August 25-26, 2020

Coverage & Reimbursement for Advanced Diagnostics

Cambridge Healthtech Institute’s 9th Annual

Publications

Pioneer Institute for Public Policy Research: “COVID testing- what went wrong, where we are, & when we’ll get closer to normalcy”
The Personalized Diagnostics Podcast: “Diagnostics- Who is the Customer?”
The Precision Medicine Podcast, by Trapelo: “Moving Diagnostics to the Forefront of Precision Medicine”

Listen in to CEO Hannah Mamuszka’s recent talks and commentary on diagnostics and their impact. The value of diagnostics has risen inestimably in the national consciousness due to the COVID-19 pandemic. Hear our viewpoints as we discuss the state of our industry and the challenges we must overcome to ensure we are diagnostic-ready for the future. Find episodes at the links below, or wherever you get your podcasts!

Summer 2020 Podcast Roundup

Listen in to CEO Hannah Mamuszka’s recent talks and commentary on diagnostics and their impact. Find episodes at the links below, or wherever you get your podcasts!

Publications

UpCOMING & Recent Events

Alva10 Videos

The pandemic has made everyone realize the importance of diagnostics in healthcare, but 8 months into the pandemic, we still lack the diagnostics we need to best manage Covid-19. How can we incentivize the development of the diagnostics we need to find disease, determine risk, and assess immunity? What are the regulatory barriers, and how can they be overcome? Who pays for these tests? What can we learn from Covid-19 for the next pandemic?

Diagnostic tests can be well validated, accepted in guidelines, and even reimbursed, yet they still don’t impact patient care. Why? Improper use, lack of physician understanding & support, lack of inclusion in coverage policies, inability to track all contribute to losing the potential impact of critical diagnostic tools. Software that highlights & streamlines decision making and provides information at the point of care allows for more efficient precision delivery of these tools.

Precision Medicine usually connotes use of diagnostics and other tools to optimize care in oncology, but really we should be considering development and use of these tools in every disease area. We will discuss the challenges around development and commercialization of Precision Medicine diagnostics for use in stroke and autoimmune diseases.

Hannah Mamuszka & Satabhisa Mukhopadhyay PhD, MS, Chief Scientific Officer & Founder, 4D Path discuss the potential for digital pathology to supplant IHC, PCR, FISH, & NGS in oncology, dramatically reducing cost & increasing patient access.

Diagnostics for Covid

How to Get What We Need

What is the potential for

Precision Medicine Outside of Oncolocy?

Precision Diagnostics 4D Path

Is it Possible to Obviate the Need for NGS Panels in Oncology with a Digital Solution?

How can Software Enable 

Diagnostics to Impact Patient Care?

October 2019— Hannah Mamuszka, CEO, Alva10 on Rethinking the Companion Diagnostic Deal Structure to Benefit All Stakeholders

Companion Diagnostics Forum

Companion Diagnostics are Bad for Diagnostic Companies